The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs

Keyphrases

• Butyric Acid 100%
• Anti-metastatic Activity 100%
• Prodrug 100%
• Bioavailable 100%
• AN-7 100%
• Histone Acetylation 40%
• Hierarchal 40%
• Oral Bioavailability 40%
• AN-9 40%
• Relative Contribution 20%
• Aldehydes 20%
• Intraperitoneal Administration 20%
• 4-fold 20%
• Tumor 20%
• Histone Deacetylase Inhibitor (HDACi) 20%
• Lung Cancer 20%
• Active Compounds 20%
• Glioblastoma Cells 20%
• Leukemic Cells 20%
• Lewis Lung Carcinoma 20%
• Fold Increase 20%
• Mononuclear Cells 20%
• Escalating Dose 20%
• Murine Lung 20%
• Lung Carcinoma 20%
• MCF-7 Cells 20%
• Anticancer Agents 20%
• In Vitro Anticancer Activity 20%
• Oral Administration 20%
• Oral Route 20%
• Lung Nodule 20%
• Lung Lesions 20%
• Astrocyte Cells 20%
• Human Breast Carcinoma 20%
• Antineoplastic Agents 20%
• Time Course Study 20%
• Lesion Formation 20%
• Metastatic Models 20%
• Intraperitoneal Route 20%
• Preferential Cytotoxicity 20%
• Ester Prodrug 20%

Medicine and Dentistry

• Prodrug 100%
• Butyric Acid 100%
• Metastasis Inhibition 100%
• In Vitro 33%
• Histone Acetylation 33%
• Antineoplastic Activity 33%
• Bioavailability 33%
• Clinical Study 16%
• Histone Deacetylase Inhibitor 16%
• Glioblastoma 16%
• Neoplasm 16%
• Lung Cancer 16%
• Intraperitoneal Drug Administration 16%
• Lewis Lung Carcinoma 16%
• Metabolite 16%
• Cytotoxicity 16%
• Breast Carcinoma 16%
• Anticarcinogen 16%
• Astrocyte 16%
• Lung Nodule 16%
• Oral Drug Administration 16%
• Lung Carcinoma 16%
• Lung Lesion 16%
• MCF-7 Cell Line 16%
• Aldehyde 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Prodrug 100%
• Butyrate 100%
• Metastasis Inhibition 100%
• Histone 33%
• Bioavailability 33%
• Histone Deacetylase Inhibitor 16%
• Glioblastoma 16%
• Neoplasm 16%
• Anticarcinogen 16%
• Clinical Study 16%
• Lewis Carcinoma 16%
• Lung Cancer 16%
• Breast Carcinoma 16%
• Lung Carcinoma 16%
• Lung Lesion 16%
• Lung Nodule 16%
• Cytotoxicity 16%
• Aldehyde 16%